EUVIMEDEUVIMED entdecken
Klinische Studie

Impact of reporting rapid susceptibility results in Gram negative bloodstream infections: a real world prospective study

Anne-Sophie Messiaen, Stien Vandendriessche, Emilie De Muynck, Gregory Strubbe, Liesbet De Bus, Petra Schelstraete, Kristen Decommer, Sanne De Smet, Alexander Soetens, Leslie Naesens, Katrien Timmermans, Jan J De Waele und 2 weitere

European Journal of Clinical Microbiology & Infectious Diseases · 2025

DOI: 10.1007/s10096-025-05046-3 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2025. Verfasst von Anne-Sophie Messiaen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Gram-Negative Bacteria, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Mortality and morbidity of patients with bloodstream infection (BSI) remain high despite advances in diagnostic methods and efforts to speed up reporting. This study investigated the impact of reporting rapid Minimum Inhibitory Concentration (MIC)-results in Gram negative BSIs with the ASTar system (Q-linea, Uppsala, Sweden) on the adaptation of empirically started antimicrobial therapy. We performed a real-world study during which antimicrobial susceptibility testing (AST) results were instantly reported to the treating physician in an established multidisciplinary antimicrobial stewardship setting. METHODS: Consecutive patients with Gram negative bacteremia were included in the study (monomicrobial Gram stain, life expectancy of at least 48 h and flagging positive before 2 PM). Rapid AST (RAST) reporting with ASTar was added on top of the standard workflow. Technical performance of the system was evaluated as well as the impact on antimicrobial treatment and timelines of achieving effective and optimal antimicrobial therapy. RESULTS: A total of 79 analyses were performed in 77 patients, of which 68 episodes were eligible for analysis. A categorical agreement was observed in 97,5% of 1160 MIC results without false susceptible results. All patients on ineffective empirical therapy (12/68) were switched after a median time of approximately one hour (5 min - 15 h) after communication of the result. Furthermore, 20/55 non-optimal therapies were adapted within a median period of 3 h after communication. CONCLUSION: The implementation of rapid MICs, measured by the ASTar system, in our low antimicrobial resistance setting with elaborate antimicrobial guidelines, was easy and led to early adaptation of empirical treatment in 32/55 instances (12 ineffective and 20 non-optimal therapy). TRIAL REGISTRATION NUMBER: NCT06218277 (date of registration: 18-12-2023).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteremiaGram-Negative BacteriaGram-Negative Bacterial InfectionsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntimicrobial StewardshipMicrobial Sensitivity TestsProspective StudiesSweden

Stichwörter der Autor:innen

Antimicrobial stewardshipEUCASTGram negative bacteremiaMICRAST

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium.
  • Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
  • Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University Ghent, Ghent, Belgium.
  • Department of Pediatric Pulmonology and Infectious Diseases, Ghent University Hospital, Ghent, Belgium.
  • Department of Internal Medicine and Infectious Diseases, Ghent University Hospital, Ghent, Belgium.
  • Laboratory of Medical Microbiology, Ghent University Hospital, Ghent, Belgium. jerina.boelens@uzgent.be.

Zitieren

APA

Messiaen, A. S., Vandendriessche, S., De Muynck, E., Strubbe, G., De Bus, L., Schelstraete, P., Decommer, K., De Smet, S., Soetens, A., Naesens, L., Timmermans, K., De Waele, J. J., Veld, D. H. I., & Boelens, J. (2025). Impact of reporting rapid susceptibility results in Gram negative bloodstream infections: a real world prospective study. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-025-05046-3

Vancouver

Messiaen AS, Vandendriessche S, De Muynck E, Strubbe G, De Bus L, Schelstraete P, et al. Impact of reporting rapid susceptibility results in Gram negative bloodstream infections: a real world prospective study. European Journal of Clinical Microbiology & Infectious Diseases. 2025. doi:10.1007/s10096-025-05046-3

BibTeX
@article{Messiaen2025,
  author = {Messiaen, Anne-Sophie and Vandendriessche, Stien and De Muynck, Emilie and Strubbe, Gregory and De Bus, Liesbet and Schelstraete, Petra and Decommer, Kristen and De Smet, Sanne and Soetens, Alexander and Naesens, Leslie and Timmermans, Katrien and De Waele, Jan J and Veld, Diana Huis In 't and Boelens, Jerina},
  title = {Impact of reporting rapid susceptibility results in Gram negative bloodstream infections: a real world prospective study},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  doi = {10.1007/s10096-025-05046-3}
}
Kostenlos starten →